A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6

Journal of Medicinal Chemistry

Volumn 42, Issue 20, 1999, Pages 4062-4070

  De Groot, Marcel J ^a   Ackland, Mark J ^a   Horne, Valerie A ^a   Alex, Alexander A ^a   Jones, Barry C ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMITRIPTYLINE; BETAXOLOL; CITALOPRAM; CLOZAPINE; CYTOCHROME P450; FLUOXETINE; IMIPRAMINE; LORATADINE; METHAMPHETAMINE; METHOXYPHENAMINE; MIANSERIN; MIRTAZAPINE; NORTRIPTYLINE; PROCAINAMIDE; PROPRANOLOL; RITONAVIR; SELEGILINE; SUMATRIPTAN;

ALKYLATION; ARTICLE; DEMETHYLATION; DRUG DESIGN; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME BINDING; HYDROXYLATION; MOLECULAR MODEL; PHARMACOPHORE; PREDICTION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; BETAXOLOL; CYTOCHROME P-450 CYP2D6; DEALKYLATION; FLUOXETINE; LORATADINE; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PROCAINAMIDE; RITONAVIR; SUBSTRATE SPECIFICITY; SUMATRIPTAN;

EID: 0033533750     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm991058v     Document Type: Article

References (71)

1. Nelson, D. R.; Koymans, L.; Kamataki, T.; Stegeman, J. J.; Feyereisen, R.; Waxman, D. J.; Waterman, M. R.; Gotoh, O.; Coon, M. J.; Estabrook, R. W.; Gunsalus, I. C.; Nebert, D. W. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996, 6, 1-42.
2. Daly, A. K.; Brockmöller, J.; Broly, F.; Eichelbaum, M.; Evans, W. E.; Gonzalez, F. J.; Huang, J. D.; Idle, J. R.; Ingelman-Sundberg, M.; Ishizaki, T.; Jacqz-Aigrain, E.; Meyer, U. A.; Nebert, D. W.; Steen, V. M.; Wolf, C. R.; Zanger, U. M. Nomenclature for human CYP2D6 allelles. Pharmacogenetics 1996, 6, 193-201.
3. Koymans, L. M. H.; Vermeulen, N. P. E.; van Acker, S. A. B. E.; te Koppele, J. M.; Heykants, J. J. P.; Lavrijsen, K.; Meuldermans, W.; Donné-Op den Kelder, G. M. A predictive model for substrates of cytochrome P-450-debrisoquine (2D6). Chem. Res. Toxicol. 1992, 5, 211-219.
4. Strobl, G. R.; von Kreudener, S.; Stöckigt, J.; Guengerich, F. P.; Wolff, T. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modelling and inhibition studies. J. Med. Chem. 1993, 36, 1136-1145.
5. de Groot, M. J.; Bijloo, G. J.; Martens, B. J.; van Acker, F. A. A.; Vermeulen, N. P. E. A refined substrate model for human cytochrome P450 2D6. Chem. Res. Toxicol. 1997, 10, 41-48.
6. Lewis, D. F. V.; Eddershaw, P. J.; Goldfarb, P. S.; Tarbit, M. H. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism. Xenobiotica 1997, 27, 319-340.
7. de Groot, M. J.; Ackland, M. J.; Horne, V. A.; Alex, A. A.; Jones, B. C. Novel approach to predicting P450 mediated drug metabolism. The development of a combined protein and pharmacophore model for CYP2D6. J. Med. Chem. 1999, 42, 1515-1524.
8. Wolff, T.; Distlerath, L. M.; Worthington, M. T.; Groopman, J. D.; Hammons, G. J.; Kadlubar, F. F.; Prough, R. A.; Martin, M. V.; Guengerich, F. P. Substrate specificity of human liver cytochrome P-450 debrisoquine hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res. 1985, 45, 2116-2122.
9. Meyer, U. A.; Gut, J.; Kronbach, T.; Skoda, C.; Meier, U. T.; Catin, T.; Dayer, P. The molecular mechanism of two common polymorphisms of drug oxidation. Evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 1986, 16, 449-464.
10. Islam, S. A.; Wolf, C. R.; Lennard, M. S.; Sternberg, M. J. E. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation. Carcinogenesis 1991, 12, 2211-2219.
11. de Groot, M. J.; Bijloo, G. J.; Hansen, K. T.; Vermeulen, N. P. E. Computer prediction and experimental validation of cytochrome P450-2D6 dependent oxidation of GBR 12909 (1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine). Drug Metab. Dispos. 1995, 23, 667-669.
12. de Groot, M. J.; Bijloo, G. J.; van Acker, F. A. A.; Fonseca Guerra, C.; Snijders, J. G.; Vermeulen, N. P. E. Extension of a predictive substrate model for human cytochrome P4502D6. Xenobiotica 1997, 27, 357-368.
13. Koymans, L. M. H.; Vermeulen, N. P. E.; Baarslag, A.; Donné-Op den Kelder, G. M. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. J. Comput.-Aided Mol. Des. 1993, 7, 281-289.
14. bm3). Xenobiotica 1995, 25, 333-366.
15. 450 2D6 based on homology modeling and NMR studies of substrate binding. Biochemistry 1996, 35, 4540-4550.
16. de Groot, M. J.; Vermeulen, N. P. E.; Kramer, J. D.; van Acker, F. A. A.; Donné-Op den Kelder, G. M. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102 and P450 108. Chem. Res. Toxicol. 1996, 9, 1079-1091.
17. Ellis, S. W.; Rowland, K.; Ackland, M. J.; Rekka, E.; Simula, A. P.; Lennard, M. S.; Wolf, C. R.; Tucker, G. T. Influence of amino acid residue 374 of cytochrome P450 2D6 (CYP2D6) on the regioand enantioselective metabolism of metoprolol. Biochem. J. 1996, 316, 647-654.
18. Poulos, T. L.; Finzel, B. C.; Gunsalus, I. C.; Wagner, G. C.; Kraut, J. The 2.6-Å crystal structure of Pseudomonas putida cytochrome P-450. J. Biol. Chem. 1985, 260, 16122-16130.
19. Poulos, T. L.; Finzel, B. C.; Howard, A. J. High-resolution crystal structure of cytochrome P450cam. J. Mol. Biol. 1987, 195, 687-700.
20. B-3, a prototype for microsomal P450s. Science 1993, 261, 731-736.
21. BM-3. Acta Crystallogr. Sect. D-Biol. Crystallogr. 1995, 51, 21-32.
22. terp at 2.3 Å resolution. J. Mol. Biol. 1994, 236, 1169-1185.
23. de Groot, M. J.; Vermeulen, N. P. E. Modeling the active site of cytochrome P450s and glutathione S-transferases, two of the most important biotransformation enzymes. Drug Metab. Rev. 1997, 29, 747-799.
24. Coutts, R. T.; Su, P.; Baker, G. B. Involvement of CYP2D6, CYP3A4, and other cytochrome P-450 isozymes in N-dealkylation reactions. J. Pharmacol. Toxicol. Methods 1994, 31, 177-186.
25. A diverse set of substrates was selected randomly from the literature from compounds not included in the training set.
26. Wave function Inc., Irvine, CA 92715. Spartan, 1996, SGI version 4.1.1 OpenGL.
27. The numbering of substrates is continued from the first part of this publication (ref 7).
28. Conformational search using the SYBYL force field employing the genetic algorithm, without geometry optimization (popsize = 150-250 depending on number of retable bonds). Of the resulting conformers, all conformers within 25 kcal/mol from the lowest energy were geometry optimized using AM1 (optcycle = 1000, maxcycle = 1000).
29. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
30. Geometry optimization using AM1 (optcycle = 1000, maxcycle = 1000).
31. Modi, S.; Gilham, D. E.; Sutcliffe, M. J.; Lian, L.-Y.; Primrose, W. U.; Wolf, C. R.; Roberts, G. C. K. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase. Biochemistry 1997, 36, 4461-4470.
32. The site of oxidation and the aromatic rings of the substrates were superimposed.
33. Tripos Inc., St. Louis, MO 63144-2913. SYBYL, 1997; Version 6.4.
34. 2)) were used. Starting orientations have aromatic ring in substrate coplanar with aromatic ring of Phe481.
35. 2).
36. The model which has the methyl of MPTP closest to the heme was selected.
37. Singh, J.; Thornton, J. M. Atlas of Protein Side-Chain Interactions; IRL Press: Oxford, 1992; Vol. 1.
38. Singh, J.; Thornton, J. M. Atlas of Protein Side-Chain Interactions; IRL Press: Oxford, 1992; Vol. 2.
39. coh substrate specificity by mutation of a single amino acid residue. Nature 1989, 399, 632-634.
40. Juvonen, R. O.; Iwasaki, M.; Negishi, M. Structural function of residue-209 in coumarin 7-hydroxylase (P450coh). Enzyme-kinetic studies and site-directed mutagenesis. J. Biol. Chem. 1991, 266, 16431-16435.
41. Iwasaki, M.; Darden, T. A.; Pedersen, L. G.; Davis, D. G.; Juvonen, R. O.; Sueyoshi, T.; Negishi, M. Engineering mouse P450coh to a novel corticosterone 15α-hydroxylase and modeling steroid-binding orientation in the substrate pocket. J. Biol. Chem. 1993, 268, 759-762.
42. 7α): role of residue-209 in determining steroid-cytochrome P-450 interaction. Biochem. J. 1993, 291, 569-573.
43. Szklarz, G. D.; Ornstein, R. L.; Halpert, J. P. Application of 3-dimensional homology modeling of cytochrome P450 2B1 for interpretation of site-directed mutagenesis results. J. Biomol. Struct. Dyn. 1994, 12, 61-78.
44. Luo, Z.; He, Y. A.; Halpert, J. R. Role of residues 363 and 206 in conversion of cytochrome P450 2B1 from steroid 16-hydroxylase to a 15α-hydroxylase. Arch. Biochem. Biophys. 1994, 309, 52-57.
45. He, Y.; Luo, Z.; Klekotka, P. A.; Burnett, V. L.; Halpert, J. R. Structural determinants of cytochrome P450 2B1 specificity: evidence for five substrate recognition sites. Biochemistry 1994, 33, 4419-4424.
46. He, Y. Q.; He, Y. A.; Halpert, J. R. Escherichia coli expression of site-directed mutants of cytochrome P450 2B1 from six substrate recognition sites: substrate specificity and inhibitor selectivity studies. Chem. Res. Toxicol. 1995, 8, 574-579.
47. Wong, Y. W. J.; Ludden, T. M. Determination of betaxolol and its metabolites in blood and urine by high-performance liquid chromatochraphy with fluorimetric detection. J. Chromatogr. 1990, 534, 161-172.
48. Mautz, D. S.; Nelson, W. L.; Shen, D. D. Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6. Drug Metab. Dispos. 1995, 23, 513-517.
49. Ferrari, S.; Leemann, T.; Dayer, P. The role of lipophilicity in the inhibition of polymorphic cytochrome P450IID6 oxidation by beta-blocking agents in vitro. Life Sci. 1991, 48, 2259-2265.
50. Hamelin, B. A.; Turgeon, J.; Vallee, F.; Belanger, P.-M.; Paquet, F.; LeBel, M. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin. Pharmacol. Ther. 1996, 60, 512-521.
51. ACD (Advanced Chemistry Development Inc.), 133 Richmond St West, Suite 605, Toronto, Canada., ACD, 1998, 3.5 (09 April 1998).
52. Yumibe, N.; Huie, K.; Chen, K.-J.; Snow, M.; Clement, R. P.; Cayen, M. N. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihisamine loratadine. Formation of descarboethoxylaratadine by CYP3A4 and CYP2D6. Biochem. Pharmacol. 1996, 51, 165-172.
53. Lessard, E.; Fortin, A.; Belanger, P. M.; Beaune, P.; Hamelin, B. A.; Turgeon, J. Role of CYP2D6 in the N-hydroxylation of procainamide. Pharmacogenetics 1997, 7, 381-390.
54. Kumar, G. N.; Rodrigues, A. D.; Buko, A. M.; Denissen, J. F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 1996, 277, 423-431.
55. Dixon, C. M.; Park, G. R.; Tarbit, M. H. Characterization of the enzyme responsible for the metabolism of Sumatriptan in human liver. Biochem. Pharmacol. 1994, 47, 1253-1257.
56. Coutts, R. T.; Bach, M. V.; Baker, G. B. Metabolism of amitriptyline with CYP2D6 expressed in a human cell line. Xenobiotica 1997, 27, 33-47.
57. Ghahramani, P.; Ellis, S. W.; Lennard, M. S.; Ramsay, L. E.; Tucker, G. T. Cytochromes P450 mediating N-demethylation of amitriptyline. Br. J. Clin. Pharmacol. 1997, 43, 137-144.
58. Olesen, O. V.; Linnet, K. Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology 1997, 55, 235-243.
59. Rochat, B.; AMey, M.; Gillet, M.; Meyer, U. A.; Baumann, P. Identification of three cytochrome P450 isozymes involved in N-demethylation of citaolpram enantiomers in human liver microsomes. Pharmacogenetics 1997, 7, 1-10.
60. Linnet, K.; Olesen, O. V. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes. Drug Met. Disp. 1997, 25, 1379-1382.
61. Grace, J. M.; Kinter, M. T.; Macdonald, T. L. Atypical metabolism of deprenyl and its enantiomer, (S)-(+)-N,α-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6. Chem. Res. Toxicol. 1994, 7, 286-290.
62. Coutts, R. T.; Su, P.; Baker, G. B.; Daneshtalab, M. Metabolism of imipramine in vitro by isozyme CYP2D6 expressed in a human cell line, and observations on metabolite stability. J. Chromatogr. Biomed. Appl. 1993, 615, 265-272.
63. Su, P.; Coutts, R. T.; Baker, G. B.; Daneshtalab, M. Analysis of imipramine and three metabolites produced by isozyme CYP2D6 expressed in a human cell line. Xenobiotica 1993, 23, 1289-1298.
64. Lin, L. Y.; di Stefano, E. W.; Schmitz, D. A.; Hsu, L.; Ellis, S. W.; Lennard, M. S.; Tucker, G. T.; Cho, A. K. Oxidation of methamphetamine and methylenedioxymetamphetamine by CYP2D6. Drug Metab. Dispos. 1997, 25, 1059-1064.
65. Geertsen, S.; Foster, B. C.; Wilson, D. L.; Cyr, T. D.; Casley, W. Metabolism of methoxyphenamine and 2-methoxyamphetamine in P4502D6-transfected cells and cell preparations. Xenobiotica 1995, 25, 895-906.
66. Koyama, E.; Chiba, K.; Tani, M.; Ishizaki, T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J. Pharmacol. Exp. Ther. 1996, 278, 21-30.
67. Dahl, M. L.; Voortman, G.; Alm, C.; Elwin, C. E.; Delbressine, L.; Vos, R.; Bogaards, J. J. P.; Bertilsson, L. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin. Drug Invest. 1997, 13, 37-46.
68. Gilham, D. E.; Cairns, W.; Paine, M. J. I.; Modi, S.; Poulsom, R.; Roberts, G. C. K.; Wolf, C. R. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 1997, 27, 111-125.
69. Olesen, O. V.; Linnet, K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab. Dispos. 1997, 25, 740-744.
70. Yoshimoto, K.; Echizen, H.; Chiba, K.; Tani, M.; Ishizaki, T. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers. N-desisopropylation is mediated mainly by CYP1A2. Br. J. Clin. Pharmacol. 1995, 39, 421-431.
71. Rowland, K.; Ellis, S. W.; Lennard, M. S.; Tucker, G. T. Variable contribution of CYP2D6 to the N-dealkylation of S-(-)-propranolol by human liver micriosomes. Br. J. Clin. Pharmacol. 1996, 42, 390-393.